AHS 2022 | Safety of eptinezumab in migraine patients

Rami Apelian, MD, MPH, FAES, Huntington Headache and Neurology, Arcadia, CA, discusses the safety information concerning eptinezumab. Eptinezumab was found to be generally safe – however, there were certain hypersensitivity reactions concerning nasal pharyngitis in 6% of the patients at the 100mg dose, 8% of the patients at the 300mg dose, and 6% with the placebo. Further hypersensitivity reactions were seen in 1% at the 100mg dose and 2% at the 300mg dose. Eptinezumab is not metabolized by the cytochrome P450 system; therefore, there are minimal drug-drug interactions. There was also no adequate data to provide recommendations in pregnant and breastfeeding women. Consequently, they do not recommend the use of eptinezumab in those populations. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.